AU2003287259A1 - The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus - Google Patents

The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus

Info

Publication number
AU2003287259A1
AU2003287259A1 AU2003287259A AU2003287259A AU2003287259A1 AU 2003287259 A1 AU2003287259 A1 AU 2003287259A1 AU 2003287259 A AU2003287259 A AU 2003287259A AU 2003287259 A AU2003287259 A AU 2003287259A AU 2003287259 A1 AU2003287259 A1 AU 2003287259A1
Authority
AU
Australia
Prior art keywords
endoperoxides
artemisinin
treatment
hepatitis
bovine viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003287259A
Other languages
English (en)
Other versions
AU2003287259A8 (en
Inventor
Eric Peys
Benedikt Sas
Johan Van Hemel
Jan Vandenkerckhove
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kemin Pharma Europe Bvba
Original Assignee
KEMIN PHARMA EUROP B A BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KEMIN PHARMA EUROP B A BV filed Critical KEMIN PHARMA EUROP B A BV
Publication of AU2003287259A1 publication Critical patent/AU2003287259A1/en
Publication of AU2003287259A8 publication Critical patent/AU2003287259A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282Artemisia, e.g. wormwood or sagebrush
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003287259A 2002-10-31 2003-10-29 The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus Abandoned AU2003287259A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42268302P 2002-10-31 2002-10-31
US60/422,683 2002-10-31
PCT/US2003/034431 WO2004041176A2 (en) 2002-10-31 2003-10-29 The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus

Publications (2)

Publication Number Publication Date
AU2003287259A1 true AU2003287259A1 (en) 2004-06-07
AU2003287259A8 AU2003287259A8 (en) 2004-06-07

Family

ID=32312544

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003287259A Abandoned AU2003287259A1 (en) 2002-10-31 2003-10-29 The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus

Country Status (11)

Country Link
US (1) US7842719B2 (enExample)
EP (1) EP1585524B1 (enExample)
JP (1) JP4594734B2 (enExample)
CN (1) CN100430061C (enExample)
AT (1) ATE473745T1 (enExample)
AU (1) AU2003287259A1 (enExample)
CA (1) CA2501584C (enExample)
DE (1) DE60333392D1 (enExample)
ES (1) ES2348536T3 (enExample)
PT (1) PT1585524E (enExample)
WO (1) WO2004041176A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE485039T1 (de) * 2003-02-12 2010-11-15 Univ Georgetown Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen
ES2245248B1 (es) * 2004-06-09 2007-02-16 Universidad De Salamanca Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos.
KR100824106B1 (ko) * 2006-05-30 2008-04-21 주식회사 씨티씨바이오 흰반점바이러스를 치료 또는 예방하기 위한 조성물 및 방법
WO2008010620A1 (en) * 2006-07-21 2008-01-24 Ben's Lab Co., Ltd. Composition comprising the crude drug extracts for improving liver function
US20080182895A1 (en) * 2006-08-25 2008-07-31 Howe Anita Y M Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
WO2009155379A2 (en) * 2008-06-17 2009-12-23 Hhv-6 Foundation Artemisinin and derivatives thereof as antivirals
CN102731464B (zh) * 2011-04-12 2014-07-23 沈阳药科大学 一个倍半萜内酯化合物、制备方法及其应用
US20130012470A1 (en) * 2011-07-07 2013-01-10 Humanitas Technology, LLC Antiviral compositions and methods of their use
WO2013006795A2 (en) 2011-07-07 2013-01-10 Humanitas International Foundation Antiviral compositions and methods of their use
DK2838903T3 (en) 2012-04-18 2017-12-11 Univ Hong Kong Sci & Tech Methods and Preparations for Treating Viral Infections
FR2989588A1 (fr) * 2012-04-19 2013-10-25 Centre Nat Rech Scient Composes pour la prevention ou le traitement des infections par des virus de la famille des flaviviridae
CN102755316A (zh) * 2012-07-16 2012-10-31 中国科学院武汉病毒研究所 青蒿素及其衍生物在制备治疗丙型肝炎病毒药物中的应用
US11007272B1 (en) 2016-10-07 2021-05-18 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
GB201805665D0 (en) * 2018-04-05 2018-05-23 Univ Nottingham Antiviral Compounds And Methods
US20210196676A1 (en) * 2018-05-30 2021-07-01 The Board Of Regents Of The University Of Texas System Treatment of viral infections and virally associated lesions with sequiterpene lactones
CN112245424B (zh) * 2020-10-19 2021-09-21 中国医学科学院医药生物技术研究所 一种没药烷倍半萜结构类似物在制备抗冠状病毒药物中的用途
CN112294795B (zh) * 2020-11-17 2022-03-29 北京化工大学 蒿甲醚在治疗和预防柯萨奇病毒感染中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW198722B (enExample) 1990-05-07 1993-01-21 Hoechst Ag
CN1058717A (zh) * 1990-08-08 1992-02-19 中国人民解放军军事医学科学院微生物流行病研究所 抗疟新药—复方蒿甲醚及其制备方法
CN1105238A (zh) * 1992-11-10 1995-07-19 中国预防医学科学院病毒学研究所 抗aids病毒的药物组合物
CN1035767C (zh) * 1992-11-10 1997-09-03 罗宣德 新的青蒿素衍生物及其用途
EP0713877A1 (en) 1993-07-19 1996-05-29 LUO, Xuande Qinghaosu derivatives against aids
DE4415539C2 (de) * 1994-05-03 1996-08-01 Osama Dr Dr Med Omer Pflanzen mit virustatischer und antiviraler Wirkung
CN1049435C (zh) * 1994-11-09 2000-02-16 中国科学院上海药物研究所 含苯基和杂环基的青蒿素衍生物及其制备方法
DE19902924A1 (de) 1999-01-26 2000-08-03 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur prophylaktischen und therapeutischen Behandlung von Infektionen
CN1135974C (zh) 2000-08-23 2004-01-28 重庆健桥医药开发有限公司 抗疟药新药复方双氢青蒿素
WO2002032905A1 (en) 2000-10-20 2002-04-25 Ajinomoto Co.,Inc. Medicinal compositions, dose and method for treating malaria
ATE485039T1 (de) * 2003-02-12 2010-11-15 Univ Georgetown Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen

Also Published As

Publication number Publication date
CN1711091A (zh) 2005-12-21
PT1585524E (pt) 2010-10-19
EP1585524A2 (en) 2005-10-19
CN100430061C (zh) 2008-11-05
ATE473745T1 (de) 2010-07-15
CA2501584C (en) 2009-03-10
US7842719B2 (en) 2010-11-30
CA2501584A1 (en) 2004-05-21
ES2348536T3 (es) 2010-12-09
WO2004041176A3 (en) 2004-10-07
AU2003287259A8 (en) 2004-06-07
JP4594734B2 (ja) 2010-12-08
WO2004041176A2 (en) 2004-05-21
EP1585524A4 (en) 2007-10-10
EP1585524B1 (en) 2010-07-14
US20050059647A1 (en) 2005-03-17
DE60333392D1 (de) 2010-08-26
JP2006504787A (ja) 2006-02-09

Similar Documents

Publication Publication Date Title
AU2003287259A1 (en) The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
AR030591A1 (es) Inhibidores de proteasa peptidomimetica
SV2005001918A (es) Metodos para preparar derivados 7-(b-d-ribofuranosilo sustituido en 2')-4 (nr2r3)-5(etin-1-ilo sustituido)-pirrol[2,3-d]pirimidina
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
ATE478886T1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
EP1455809A4 (en) INHIBITORS OF HEPATITIS C VIRUSES
PE20040751A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE DOSIS BAJAS DE UN INHIBIDOR DEL TNFalfa HUMANO
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
PA8573401A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan
CL2004000710A1 (es) Composicion antimicrobiana y antiparasitaria formada por un antibiotico derivado del cloranfenicol o tianfenicol, un endectocida y por lo menos un vehiculo aceptable, y su uso para tratar enfermedades respiratorias y parasitarias de los bovinos.
WO2004112720A3 (en) Antiviral compositions and methods of using the same
WO2006101538A3 (en) Andrographolide derivatives to treat viral infections
EA200700718A1 (ru) Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения
EP1749885A3 (en) Infectious and attenuated bovine viral diarrhea virus clones; methods for their production and use
NO20053348L (no) Farmasoytisk sammensetning for behandling av virusangrep.
WO2002015664A3 (en) Methods of preventing or treating west nile virus and other infections
WO2004062575A3 (en) Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
WO2003051301A3 (en) USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
DiK et al. In vitro antiviral and antioxidant activities of silymarin and panax ginseng on vero cells infected with bovine ephemeral fever virus and blue tongue virus
AR061949A1 (es) Uso de nitro derivados de flavonas como agentes inductores de apoptosis para la preparacion de un medicamento
Ahmad Phytochemical and biological studies on Goniothalamus spp. endemic to Borneo
DK0557348T3 (da) Avermectiner og milbemyciner til behandling af parasitinfektioner hos hunde
EA200100227A1 (ru) Соединения, композиции и способы лечения или предупреждения вирусных инфекций и связанных с ними заболеваний

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase